-
NMPA Announcement on Revising the Package Inserts of Sulfasalazine Preparations
2021-01-14
To further protect public medication safety, the NMPA decided to revise the package inserts of Sulfasalazine Preparations. The relevant issues are hereby announced as follows.
-
NMPA Announcement on Issuing the Provisions for the Change Management of Post-approval Drugs (Interim)
2021-01-13
The NMPA organized to formulate of the Provisions for Change Management of Post-approval Drugs (Interim), is hereby promulgated and shall go into effect as of January 12, 2021.
-
SAMR Issued the Provisions for Registration and Notification of Cosmetics
2021-01-12
The NMPA drafted the Provisions for Registration and Notification of Cosmetics (hereinafter referred to as the Provisions). The Provisions has been adopted upon deliberation at the 14th Executive Meeting of the State Administration of Market Regulation on December 31, 2020, and shall go into effect as of May 1, 2021.
-
NMPA Announcement on Issues Pertaining to Online Application for Drug Registration Affairs
2020-12-28
The NMPA has enabled and officially launched on January 1, 2021 the online application module for drug registration affairs.
-
SAMR Released the Provisions for the Lot Release of Biological Products
2020-12-21
NMPA drafted the Provisions for the Lot Release of Biological Products (hereinafter referred to as the Provisions ).
-
Center for Drug Evaluation of NMPA Announced on Issuing the Administrative Measures for Communication of Drug R&D and Technical Review
2020-12-11
The Center for Drug Evaluation organized the revision of the Administrative Measures for Communication of Drug R&D and Technical Review, been released with NMPA's examination and approval for implementation as from December 10, 2020.